Thu, Jul 24, 2014, 2:04 AM EDT - U.S. Markets open in 7 hrs 26 mins

Recent

% | $
Click the to save as a favorite.

Arena Pharmaceuticals, Inc. Message Board

  • spook2b spook2b Feb 8, 2013 4:36 PM Flag

    Blackrock filing out

    Shows they've got 12,859,067 ARNA shares, or 5.92% of shares o/s

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • where is that at??? yahoo show them as 2 mill since sept.

      Sentiment: Strong Buy

    • SECURITIES AND EXCHANGE COMMISSION

      Washington, D.C. 20549

      SCHEDULE 13G

      Under the Securities Exchange Act of 1934

      (Amendment No: 3)

      ARENA PHARMACEUTICALS INC.
      (Name of Issuer)

      Common Stock
      (Title of Class of Securities)

      040047102
      (CUSIP Number)

      December 31, 2012
      (Date of Event Which Requires Filing of this Statement)
      Check the appropriate box to designate the rule pursuant to
      which this Schedule is filed:

      [X] Rule 13d-1(b)
      [ ] Rule 13d-1(c)
      [ ] Rule 13d-1(d)

      *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

      The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

      CUSIP No. 040047102

      (1)Names of reporting persons. BlackRock, Inc.

      (2) Check the appropriate box if a member of a group
      (a) [ ]
      (b) [X]

      (3) SEC use only

      (4) Citizenship or place of organization

      Delaware

      Number of shares beneficially owned by each reporting person with:

      (5) Sole voting power

      12859067

      (6) Shared voting power

      None

      (7) Sole dispositive power

      12859067

      (8) Shared dispositive power

      None

      (9) Aggregate amount beneficially owned by each reporting person

      12859067

      (10) Check if the aggregate amount in Row (9) excludes certain shares

      (11) Percent of class represented by amount in Row 9

      5.92%

      (12) Type of reporting person

      HC

      Item 1.

      Item 1(a) Name of issuer:
      -----------------------------------------------------------------------

      ARENA PHARMACEUTICALS INC.

      Item 1(b) Address of issuer's principal executive offices:
      -----------------------------------------------------------------------

      6166 Nancy Ridge DR
      San Diego CA 92121

      Item 2.

      2(a) Name of person filing:
      ----------------------------------------------------------------------
      BlackRock, Inc.

      2(b) Address or principal business office or, if none, residence:
      -----------------------------------------------------------------------
      BlackRock Inc.
      40 East 52nd Street
      New York, NY 10022

      2(c) Citizenship:
      --------------------------------------------------------------------
      See Item 4 of Cover Page

      2(d) Title of class of securities:
      -------------------------------------------------------------------

      Common Stock

      2(e) CUSIP No.:
      See Cover Page

      Item 3.

      If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c),
      check whether the person filing is a:
      [ ] Broker or dealer registered under Section 15 of the Act;
      [ ] Bank as defined in Section 3(a)(6) of the Act;
      [ ] Insurance company as defined in Section 3(a)(19) of the Act;
      [ ] Investment company registered under Section 8 of the
      Investment Company Act of 1940;
      [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      [ ] An employee benefit plan or endowment fund in accordance with
      Rule 13d-1(b)(1)(ii)(F);
      [X] A parent holding company or control person in accordance with
      Rule 13d-1(b)(1)(ii)(G);
      [ ] A savings associations as defined in Section 3(b) of the Federal
      Deposit Insurance Act (12 U.S.C. 1813);
      [ ] A church plan that is excluded from the definition of an
      investment company under section 3(c)(14) of the Investment Company
      Act of 1940;
      [ ] A non-U.S. institution in accordance with
      Rule 240.13d-1(b)(1)(ii)(J);
      [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing
      as a non-U.S. institution in accordance with
      Rule 240.13d-1(b)(1)(ii)(J), please specify the type of
      institution:

      Item 4. Ownership

      Provide the following information regarding the aggregate number
      and percentage of the class of securities of the issuer identified in Item 1.

      Amount beneficially owned:

      12859067

      Percent of class

      5.92%

      Number of shares as to which such person has:

      Sole power to vote or to direct the vote

      12859067

      Shared power to vote or to direct the vote

      None

      Sole power to dispose or to direct the disposition of

      12859067

      Shared power to dispose or to direct the disposition of

      None

      Item 5.

      Ownership of 5 Percent or Less of a Class. If this statement is being
      filed to report the fact that as of the date hereof the reporting person
      has ceased to be the beneficial owner of more than 5 percent of the
      class of securities, check the following [ ].

      Item 6. Ownership of More than 5 Percent on Behalf of Another Person

      If any other person is known to have the right to receive or the power
      to direct the receipt of dividends from, or the proceeds from the sale
      of, such securities, a statement to that effect should be included in
      response to this item and, if such interest relates to more than 5 percent
      of the class, such person should be identified. A listing of the
      shareholders of an investment company registered under the Investment
      Company Act of 1940 or the beneficiaries of employee benefit plan,
      pension fund or endowment fund is not required.

      Various persons have the right to receive or the power to direct
      the receipt of dividends from, or the proceeds from the sale of
      the common stock of
      ARENA PHARMACEUTICALS INC..
      No one person's interest in the common stock of
      ARENA PHARMACEUTICALS INC.
      is more than five percent of the total outstanding common shares.

      Item 7. Identification and Classification of the Subsidiary Which
      Acquired the Security Being Reported on by the Parent Holding
      Company or Control Person.

      See Exhibit A

      Item 8. Identification and Classification of Members of the Group

      If a group has filed this schedule pursuant to Rule 13d-1(b)(ii)(J),
      so indicate under Item 3(j) and attach an exhibit stating the identity
      and Item 3 classification of each member of the group. If a group
      has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d),
      attach an exhibit stating the identity of each member of the group.

      Item 9. Notice of Dissolution of Group

      Notice of dissolution of a group may be furnished as an exhibit
      stating the date of the dissolution and that all further filings with
      respect to transactions in the security reported on will be filed,
      if required, by members of the group, in their individual capacity.

      See Item 5.

      Item 10. Certifications
      By signing below I certify that, to the best of my knowledge and
      belief, the securities referred to above were acquired and are
      held in the ordinary course of business and were not acquired
      and are not held for the purpose of or with the effect of changing
      or influencing the control of the issuer of the securities and were
      not acquired and are not held in connection with or as a participant
      in any transaction having that purpose or effect.

      Signature.

      After reasonable inquiry and to the best of my knowledge and
      belief, I certify that the information set forth in this statement
      is true, complete and correct.

      Dated: February 4, 2013
      BlackRock, Inc.

      Signature: Matthew J. Fitzgerald

      -------------------------------------------

      Name/Title Attorney-In-Fact

      The original statement shall be signed by each person on whose
      behalf the statement is filed or his authorized representative.
      If the statement is signed on behalf of a person by his authorized
      representative other than an executive officer or general partner
      of the filing person, evidence of the representative's authority to
      sign on behalf of such person shall be filed with the statement,
      provided, however, that a power of attorney for this purpose
      which is already on file with the Commission may be incorporated
      by reference. The name and any title of each person who
      signs the statement shall be typed or printed beneath his signature.

      Attention: Intentional misstatements or omissions of fact constitute
      Federal criminal violations (see 18 U.S.C. 1001).

      Exhibit A

      Subsidiary

      BlackRock Advisors, LLC
      BlackRock Investment Management, LLC
      BlackRock Investment Management (Australia) Limited
      BlackRock Asset Management Canada Limited
      BlackRock Advisors (UK) Limited
      BlackRock Fund Advisors
      BlackRock International Limited
      BlackRock Institutional Trust Company, N.A.
      BlackRock Japan Co. Ltd.
      BlackRock Investment Management (UK) Limited

      *Entity beneficially owns 5% or greater of the outstanding
      shares of the security class being reported on this
      Schedule 13G.
      Exhibit B

      POWER OF ATTORNEY

      The undersigned, BLACKROCK, INC., a corporation duly organized
      under the laws of the State of Delaware, United States (the
      "Company"), does hereby make, constitute and appoint each of
      Matthew Mallow,Howard Surloff,Edward Baer, Bartholomew Battista,
      Dan Waltcher, Karen Clark, Daniel Ronnen,John Stelley, Brian Kindelan,
      John Blevins, Richard Froio, Matthew Fitzgerald and Con Tzatzakis acting
      severally, as its true and lawful attorneys-in-fact, for the purpose of,
      from time to time,executing in its name and on its behalf, whether the
      Company is acting individually or as representative of others, any and
      all documents, certificates, instruments, statements, other filings and
      amendments tothe foregoing (collectively, "documents") determined by
      such person to be necessary or appropriate to comply with ownership or
      control-person reporting requirements imposed by any United States
      or non-United States governmental or regulatory authority, including
      without limitation Forms 3, 4, 5, 13D, 13F, 13G and 13H and any
      amendments to any of the foregoing as may be required to be filed
      with the Securities and Exchange Commission, and delivering,
      furnishing or filing any such documents with the appropriate
      governmental, regulatory authority or other person, and giving and
      granting to each such attorney-in-fact power and authority to act in
      the premises as fully and to all intents and purposes as the Company
      might or could do if personally present by one of its authorized
      signatories, hereby ratifying and confirming all that said
      attorney-in-fact shall lawfully do or cause to be done by
      virtue hereof. Any such determination by an attorney-in-fact named
      herein shall be conclusively evidenced by such person's execution,
      delivery, furnishing or filing of the applicable document.

      This power of attorney shall expressly revoke the power of attorney
      dated 30th day of November,2011 in respect of the subject matter hereof,
      shall be valid from the date hereof and shall remain in full force and
      effect until either revoked in writing by the Company, or, in respect of
      any attorney-in-fact named herein, until such person ceases to be an
      employee of the Company or one of its affiliates.

      IN WITNESS WHEREOF, the undersigned has caused this power of
      attorney to be executed as of this 10th day of July, 2012.

      BLACKROCK, INC.

      By:_ /s/ Chris Leavy
      Name: Chris Leavy
      Title: Chief Investment Officer

      Sentiment: Strong Buy

    • WHERE DO YOU GET THESE #S

    • This is good

      Sentiment: Strong Buy

    • Just follow the money........strong buy seems to be the action from Blackrock with a double up in shares. Awesome bull move.

      Sentiment: Strong Buy

 
ARNA
4.875+0.040(+0.83%)Jul 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.